63
correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers,
Hum. Pathol. 2008 (Epub ahead of print).
[26] G. Soufla, F. Porichisa, G. Sourvinosa, S. Vassilarosb, D.A. Spandidosa, Transcriptional
deregulation of VEGF, FGF2, TGF-b1, 2, 3 and cognate receptors in breast tumorigenesis,
Cancer Lett. 235 (2006), pp. 100–113.
[27] J.A. Shaw, K. Udokang, J.M. Mosquera, H. Chauhan, J.L. Jones, R.A. Walker,.,
Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas, J.
Pathol. 198 (2002), pp. 450−457.
[28] Y. Omoto, S. Kobayashi, S. Inoue, S. Ogawa, T. Toyama, H. Yamashita et al.,
Evaluation of oestrogen receptor beta wild-type and variant protein expression, and
relationship with clinicopathological factors in breast cancers, Eur. J. Cancer 38 (2002), pp.
380−386.
[29] R. Brockmann, A. Beyer, J.J Heinisch, T. Wilhelm, Posttranscriptional Expression
Regulation: What Determines Translation Rates?, PLoS Comput. Biol. 3 (2007), pp. e57.
[30] H. Gobbi, C.L. Arteaga, R.A. Jensen, J.F. Simpson, W.D. Dupont, S.J. Olson et al.,
Loss of expression of transforming growth factor beta type II receptor correlates with high
tumour grade in human breast in-situ and invasive carcinomas, Histopathology 36 (2000), pp.
168-177.
[31] S.B. Jakowlew, Transforming growth factor-β in cancer and metastasis, Cancer
Metastasis Rev. 25 (2006), pp. 435–457.
[32] A. Tripathi, C. King, A. de la Morenas, V.K. Perry, B. Burke, G.A. Antoine et al., Gene
expression abnormalities in histologically normal breast epithelium of breast cancer patients,
Int. J. Cancer 122 (2008), pp. 1557-1566.
[33] K.D. Amoils, W.R. Bezwoda, TGF-b1 mRNA expression in clinical breast cancer and
its relationship to ER mRNA expression, Breast Cancer Res. Treat. 42 (1997), pp. 95-101.
[34] M. Cianfrocca, L.J. Goldstein, Prognostic and Predictive Factors in Early-Stage Breast
Cancer, Oncologist 9 (2004), pp. 606-616.
[35] A. Stoica, M. Saceda, A. Fakhro, H.B. Solomon, B.D. Fenster, M.B. Martin, The Role of
Transforming Growth Factor-b in the Regulation of Estrogen Receptor Expression in the
MCF-7 Breast Cancer Cell Line, Endocrinol. 138 (1997), pp. 1498–1505.
[36] C. Knabbe, G. Zugmaier, M. Schmahl, M. Dietel, M.E. Lippman, R.B. Dickson,
Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifen, and
toremifene in MCF-7 cells, Am. J. Clin. Oncol. 14 (Suppl. 2) (1991), pp. S15-20.